Alexandros Fotopoulos - 15 Jun 2023 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Signature
/s/ Edgar Cale, Attorney-in-Fact
Issuer symbol
PASG
Transactions as of
15 Jun 2023
Net transactions value
-$3,778
Form type
4
Filing time
20 Jun 2023, 16:10:44 UTC
Previous filing
05 Apr 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PASG Common Stock Options Exercise $0 +12,500 +62% $0.000000 32,745 15 Jun 2023 Direct F1
transaction PASG Common Stock Sale $3,778 -4,052 -12% $0.9325 28,693 16 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PASG Restricted Stock Units Options Exercise $0 -12,500 -33% $0.000000 25,000 15 Jun 2023 Common Stock 12,500 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3 1/4 of the RSUs vested on June 15, 2022, and the remainder vested or vests as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4 These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.